je.st
news
Tag: financial
School Specialty Appoints Ryan M. Bohr as Its New Chief Financial Officer
2014-10-29 20:33:27| Furniture - Topix.net
School Specialty, Inc. , a leading distributor of innovative and proprietary products, programs and services to the education marketplace, is pleased to announce the appointment of Ryan M. Bohr as its new Executive Vice President and Chief Financial Officer, effective immediately. Mr. Bohr replaces Kevin Baehler, who was named Interim Chief Financial Officer in January 2014.
Tags: school
financial
chief
officer
Auto Dealers Drive Third-quarter Profits Higher At Ally Financial
2014-10-29 16:36:34| Auto Dealers - Topix.net
Commercial auto loan balances, which includes the financing of dealers' inventories, real estate and other operations, increased around 11 percent to around $31 billion. That pace was nearly double the growth in consumer auto loan balances over the same period.
Tags: auto
drive
financial
higher
Landauer, Inc. (LDR) - Financial and Strategic SWOT Analysis Review - New Study Released
2014-10-29 05:24:00| Waste Management - Topix.net
The company provides integrated radiation safety products and services that include occupational radiation monitoring, professional medical physics and medical products. Landaueri 1 2s products include dosimeters, dosimetry program reporting, radiation monitoring hardware, radiation monitoring software and dosimetry system solutions.
Tags: new
review
study
analysis
Nike, Inc. Has Strong Financial, Operating And Dividend Metrics
2014-10-27 20:48:22| Footwear - Topix.net
Late September, NKE reported better than expected fiscal first quarter 2015 earnings per share of $1.09, up 27% from the prior year. The company enjoys strong financial, operating and dividend metrics.
Tags: strong
financial
operating
nike
Merck Announces Third-Quarter 2014 Financial Results
2014-10-27 12:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Third-Quarter 2014 Non-GAAP EPS of $0.90, Excluding Certain Items, and GAAP EPS of $0.31 Narrows 2014 Full-Year Non-GAAP EPS Target to $3.46 to $3.50, Excluding Certain Items; Updates 2014 Full-Year GAAP EPS Target to $4.06 to $4.29; Now Expects 2014 Full-Year Revenues to be Between $42.4 Billion and $42.8 Billion Generated Worldwide Sales of $10.6 Billion, a Decrease of 4 Percent, Reflecting Unfavorable Impact of Divested Products, Patent Expiries and Decline in Sales of Hepatitis C Products Increased Sales of Acute Care, Immunology, Diabetes and Animal Health Products FDA Approved KEYTRUDA for the Treatment of Advanced Melanoma in Patients Who Have Progressed after Other Therapies and BELSOMRA for the Treatment of Insomnia KEYTRUDA Received Breakthrough Therapy Designation from the FDA for Patients with Advanced Non-Small Cell Lung Cancer Who Have Progressed Following Platinum-Containing Chemotherapy WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2014. Language: English Contact: MerckMedia:Steve Cragle, 908-423-3461Lainie Keller, 908-236-5036orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Sites : [362] [363] [364] [365] [366] [367] [368] [369] [370] [371] [372] [373] [374] [375] [376] [377] [378] [379] [380] [381] next »